冰岛阿特维斯（Actavis）   
全球领先的仿制药制造商Actavis Inc(NYSE：ACT)(原华生制药)
2012年10月，原华生制药公司(Watson Pharmaceuticals)斥资56亿美元收购了瑞士制药商Actavis Group之后，并将公司名改为Actavis Inc，将股票代码从“WPI”改为“ACT”。

冰岛著名Actavis生物制药公司成立于1956年，于2005年并购国际制药公司Alpharma后，已成为世界上第四大生物制药公司。该公司是冰岛第一大制药企业，现有雇员10000多名。是冰岛证券交易所上市企业，目前市值约20亿美元。该公司在32个国家有经营业务，生产和销售650多种药品，300余种新药正在研发中。市场分布以欧美为主，05-06年通过并购，进入并占据俄罗斯、罗马尼亚等东欧市场的一定份额。主要产品：心血管药物系列、中枢神经药物系列、抗感染药物系列等
阿特维斯是世界领先的普药企业之一，专注于普药的研发、制造和销售。1956年成立于冰岛，当时的名称为Pharmaco，2004年更名为Actavis。1997年于冰岛股票交易所登记上市，1999年建立国际发展战略,向国际市场进军，实施一系列收购行动，到2005年成功并购美国雅来的人类普药业务后公司已经跃居全球第四大普药企业。2006年公司的市场价值约30亿欧元（38亿美元），2004年营业额为12亿欧元，预计2007年营业额将达到15.5亿欧元。公司目前在30多个国家经营业务，雇员超过11000名，拥有240 亿片剂的生产能力，在市场上销售600多种产品，主要覆盖：中枢神经、心血管、消化、代谢、骨骼肌肉、抗感染、呼吸系统及其它类别。在行业内我们著称于：成长最快的公司，定位一流品质普药市场，注册最多新产品的公司，成功并购（最多）的纪录，具有挑战性同时又令人兴奋的工作环境。因为阿特维斯的愿景是成为国际普药市场上研发，制造和销售合格产品的旗舰。ACTAVIS就是：ACTA=Action行动 + VIS=Strength力量，Actavis还代表：Vital 有生命力的，Ambitious 有雄心的，Speedy 迅速的，Decisive 果断的，Innovative 创新的，Pro-active 积极主动的 ，Reliable 可信赖的 ，Modern 现代化的，International 国际化的 。


Actavis Foshan is an important manufacturing site in Asia. The Guangdong plant employs 300 staff producing antibiotics and other products for use in the treatment of the digestive and cardiovascular system. Dosage forms include tablet, soft gel capsule, hard capsule, oral solution, dry suspension, ointments and liniments.

The Actavis (Foshan) Pharmaceutical Co., Ltd. is a joint venture between the Actavis Group and Foshan Chanbende Development Co., Ltd.

The Actavis Group is one of the world’s leading players in the development, manufacture and sale of high-quality generic pharmaceuticals. The successful integration of a number of acquisitions has helped position Actavis among the world’s largest companies in the industry. Founded in 1956, the Group has more than 10,000 employees operating in about 40 countries around the globe. Its headquarters are in Iceland.

The Company has modern development and manufacturing facilities in Europe, the US and Asia. The plants produce a variety of medicines in different formulations including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids and semi-solids.

Product portfolio

Actavis offers one of the broadest product portfolios and strongest pipelines in the generics industry:

Around 830 products on the market
Over 350 products under development and pending registration
Products registered in more than 60 countries
Over 660 product and market launches in Group markets in 2008

Future opportunities

An extensive network of sales and marketing offices enables effective market penetration, positioning the Group strongly in the world’s largest markets for generic pharmaceuticals. Strategic acquisitions, the opening of new sales offices and intensive investment in the development of generic pharmaceuticals are fuelling the growth of Actavis and have positioned the Group to take advantage of future opportunities.

The Group remains committed to leading the consolidation of a still fragmented industry through strategic acquisitions and to driving further organic growth through innovative product launches, penetration of new markets and regulatory approvals of new generic pharmaceuticals.

Actavis continues to invest heavily in research and development, pursuing a determined first-to-market strategy and positioning itself to take full advantage of future opportunities.